NeuroMetrix (NASDAQ:NURO) and Daxor (NASDAQ:DXR) Head to Head Survey

Daxor (NASDAQ:DXR) and NeuroMetrix (NASDAQ:NURO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Institutional and Insider Ownership

1.3% of Daxor shares are held by institutional investors. Comparatively, 19.4% of NeuroMetrix shares are held by institutional investors. 59.0% of Daxor shares are held by insiders. Comparatively, 7.3% of NeuroMetrix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Daxor and NeuroMetrix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
NeuroMetrix	-203.71%	-42.56%	-39.26%

Valuation & Earnings

This table compares Daxor and NeuroMetrix”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	$2.13 million	17.59	N/A	N/A	N/A
NeuroMetrix	$3.03 million	3.09	-$6.53 million	($4.59)	-0.99

Daxor has higher earnings, but lower revenue than NeuroMetrix.

Risk & Volatility

Daxor has a beta of -0.21, suggesting that its share price is 121% less volatile than the S&P 500. Comparatively, NeuroMetrix has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Daxor and NeuroMetrix, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0	0	1	0	3.00
NeuroMetrix	0	0	0	0	0.00

Daxor presently has a consensus price target of $25.00, suggesting a potential upside of 222.58%. Given Daxor’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Daxor is more favorable than NeuroMetrix.

Summary

Daxor beats NeuroMetrix on 8 of the 11 factors compared between the two stocks.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

About NeuroMetrix

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.